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Previous experience with antimicrobial resistance has
emphasized the importance of appropriate stewardship of
these pharmacotherapeutic agents. The introduction of fluoro-
quinolones provided potent new drugs directed primarily
against gram-negative pathogens, while the newer members of
this class demonstrate more activity against gram-positive spe-
cies, including Streptococcus pneumoniae. Although these
agents are clinically effective against a broad range of infec-
tious agents, emergence of resistance and associated clinical
failures have prompted reexamination of their use. Appropriate
use revolves around two key objectives: 1) only prescribing
antimicrobial therapy when it is beneficial and 2) using the
agents with optimal activity against the expected pathogens.
Pharmacodynamic principles and properties can be applied to
achieve the latter objective when prescribing agents belonging
to the fluoroquinolone class. A focused approach emphasizing
“correct-spectrum” coverage may reduce development of anti-
microbial resistance and maintain class efficacy. 
evelopment of resistance to antimicrobial agents and the
emergence of multiresistant pathogens have generated
worldwide concern in the medical community. Infections
caused by resistant bacteria are associated with higher rates of
hospitalization, greater length of hospital stay, and higher rates
of illness and death (1,2). The estimated annual cost of treating
infections caused by resistant bacteria in the United States is
several billion dollars (3).
Antimicrobial resistance develops when bacteria are
exposed to an antimicrobial agent, and selective pressure
favors the growth of the resistant pathogen. To decrease selec-
tive pressure, antibacterial therapy should only be prescribed
in patients with known or suspected bacterial infections. The
risk for resistance can be further reduced by using an antimi-
crobial agent that has potent activity against the suspected
pathogens at the dose and dosing frequency that maximizes its
effectiveness.
Historically, several approaches to antibiotic prescribing
have been employed to address antimicrobial resistance. One
approach is to use a newer more potent antimicrobial in set-
tings where resistance has emerged to an older agent. How-
ever, if newer agents are overused or used inappropriately,
resistance will invariably develop to the newer drug. For
example, since the late 1980s and early 1990s, ceftazidime, a
third-generation cephalosporin, has been widely used against
gram-negative pathogens, including Pseudomonas. However,
indiscriminate use led to decreased activity against gram-nega-
tive infections and may have contributed to emergence of
potent broad-spectrum β -lactamases among Enterobacter, Cit-
robacter, Klebsiella, and other gram-negative species (4–7).
Another approach to combating resistance is to continue using
older agents as first-line choices, in preference to newer, more
potent drugs, in an effort to preserve the activity of the new
drugs. The newer agents are reserved for infections caused by
mutated multiresistant strains. However, as resistance contin-
ues to increase to the first-line agents, poor outcomes and sec-
ondary costs associated with clinical failures increase. By
withholding the more potent agents for selected cases, these
agents are increasingly compromised by the emergence of
mutants selected by the less potent compounds. 
An approach designed to reduce the rate at which antibi-
otic resistance develops is antibiotic cycling or rotation. It has
been used with some success in intensive-care units (ICUs),
where one class of agent has been predominantly used for a
predefined period, usually 3 months, followed by use of
another class for 3 months. Although not widely used, rotation
has been used succesfully by Kollef  et al. (8). A second
approach is the use of combination therapy, whereby the addi-
tive or synergistic action of two or more drugs is exploited.
Overall, resistance potential is theoretically minimized by this
technique since these agents are typically from different anti-
microbial classes, and different sites in the bacterial cell are
targeted. Finally, a more focused approach of using the agents
that demonstrate the best pharmacokinetic and pharmacody-
namic profile against suspected pathogens might also reduce
antimicrobial resistance. The objective of this approach is to
predictably eradicate bacteria so that resistant clones are not
selected. 
The fluoroquinolone class of antimicrobial agents is being
used empirically in an increasing number of patients because
resistance has developed to the more traditional empiric
agents. Fluoroquinolones are active against a wide range of
multiresistant pathogens since their mode of action is against
different molecular targets than other antimicrobial classes (9).
Moreover, mechanisms of resistance to fluoroquinolones,
apart from two unusual exceptions (10,11), are unlike almost
all other class resistance mechanisms, being neither plasmid
nor integron mediated. 
We propose a strategy to preserve susceptibilities to this
important antimicrobial class. Appropriate and targeted use of
the fluoroquinolone class is discussed and analyzed within the
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context of in vitro, pharmacokinetic, and pharmacodynamic
activity. The epidemiologic and clinical aspects of fluoroqui-
nolone usage are outlined in an attempt to identify outcome-
optimizing drug selection strategies. Finally, once fluoroqui-
nolone therapy has been chosen, evidence-based strategies for
how this antimicrobial class can be used to minimize develop-
ment of drug resistance are discussed.
Fluoroquinolone Differentiation: in vitro Perspectives
Individual members of the fluoroquinolone class demon-
strate different spectra of activity and pharmacokinetic pro-
files. The first-generation fluoroquinolones (e.g.,
ciprofloxacin, ofloxacin, norfloxacin) are primarily active
against gram-negative and some gram-positive organisms. The
second-generation fluoroquinolone, levofloxacin, is the L-iso-
mer of ofloxacin and demonstrates somewhat improved gram-
positive activity. However, susceptibility data show levofloxa-
cin to be less potent than ciprofloxacin against such gram-neg-
ative pathogens as Pseudomonas aeruginosa and certain
enterobacteriaceae (12). The third-generation fluoroquinolo-
nes include moxifloxacin and gatifloxacin and have improved
gram-positive, atypical, and anaerobic coverage compared
with first- and second-generation fluoroquinolones. In particu-
lar, these newer representatives of the fluoroquinolone class
manifest greater activity against Streptococcus pneumoniae, an
important respiratory pathogen (12).
The relative activities of these fluoroquinolones, expressed
as 90% MICs (MIC90s), are shown in Table 1. Ciprofloxacin is
the most active fluoroquinolone against P. aeruginosa; typical
MICs of ciprofloxacin are two- to eightfold lower than those
of levofloxacin or newer quinolones such as moxifloxacin and
gatifloxacin (12–16). Species of enterobacteriaceae also differ
in their susceptibility to the quinolones (12). Ciprofloxacin is
generally twofold more active against Escherichia coli and
Klebsiella pneumoniae than levofloxacin and moxifloxacin
(Table 1). 
Conversely, ciprofloxacin (1.0–4.0 mg/L) and levofloxacin
(1.0–2.0  mg/L) are not as active against S. pneumoniae as
moxifloxacin (0.06–0.25 mg/L) or gatifloxacin (0.5–1.0 mg/L)
(12–16). A recent survey conducted in the United States and
Canada showed ciprofloxacin MIC90s of 2 mg/L against S.
pneumoniae to be identical to those of levofloxacin but higher
than those of the third-generation fluoroquinolone gatifloxacin
(0.5 mg/L) (17). In addition to improved gram-positive activ-
ity, third-generation fluoroquinolones have improved activity
against some anaerobic species compared to first- and second-
generation fluoroquinolones. MIC90s for Prevotella/Porphy-
romonas, Fusobacterium species, and Peptostreptococcus spe-
cies for levofloxacin are 1.0–8.0, 1.0–8.0, and 4.0 mg/L, as
compared with moxifloxacin (0.5–4.0,0.125–4.0, and 0.5 mg/
L), respectively (18). Activity of newer fluoroquinolones
against a variety of atypical organisms is also improved. For
Table 1. Comparison of in vitro activitya of four fluoroquinolones against a range of pathogensb
Fluoroquinolone E. coli P. aeruginosa K. pneumoniae S. pneumoniaec S. aureusd Ref.
Ciprofloxacin 0.03 8 NR 4 0.5 12
0.125–0.5 0.25–4 0.25 1-2 0.5–1 13
0.016 8 0.06 4 0.5 14
0.016 2 0.25 2 0.5 15
0.25 4 0.06 2 1 16
Levofloxacin NR 32 NR 2 0.25 12
0.06–<0.5 0.5–>4 0.12–0.25 1–2 0.25 13
0.03 32 0.13 2 0.25 14
0.06 4 0.25 2 0.25 15
0.12 16 0.12 1 0.5 16
Moxifloxacin 0.06 8 NR 0.25 0.06 12
0.06–1 8 0.12–0.25 0.06–0.25 0.12 13
0.008 32 0.13 0.25 0.06 14
0.06 8 0.5 0.25 0.06 15
0.5 8 0.5 0.25 0.12 16
Gatifloxacin NR 32 NR 1.0 0.125 12
0.06 >4 0.06–0.25 0.5 0.12 13
0.016 32 0.13 1 0.13 14
0.1 8 0.12 0.5 0.12 15
aMIC90 reported.
bE. coli, Escherichia coli; P. aeruginosa, Pseudomonas aeruginosa; K. pneumoniae, Klebsiella pneumoniae;  S. pneumoniae, Streptococcus pneumoniae; S. aureus, Staphylococcus 
aureus; NR, not reported.
cPenicillin-susceptible S. pneumoniae, except in the case of Reference 12, which did not specify.
dMethicillin-susceptible S. aureus, except in the case of Reference 12, which did not specify.Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 3
PERSPECTIVES
example, for Mycoplasma pneumoniae, MICs are 1.0 mg/Land
0.5 mg/L for ciprofloxacin and levofloxacin, respectively, and
0.125 mg/L for both moxifloxacin and gatifloxacin (19).
Fluoroquinolone MIC90s will increase as resistant mutants
invariably emerge, although the rate at which resistance devel-
ops largely depends on appropriate use. Patient-, institution-,
and infection-specific therapeutic decisions require that anti-
microbial susceptibilities be routinely tested and reported.
Accurately assessing these MIC changes depends on the preci-
sion of the test used. The standard doubling dilution tech-
niques used in most hospital microbiology laboratories may
not be precise enough to identify minor susceptibility changes
within a bacterial population (20). Utilizing the E-test method,
which is sensitive enough to detect these subtle MIC changes
(21), as follow-up for monitoring and controlling resistant
strains isolated with increasing frequency in the clinical labo-
ratory might be a practical solution, even though this approach
requires greater resource and acquisition costs. Detecting and
reporting these susceptibility changes are important since they
can predict changes in the resistance potential of a pathogen
(22). These data may be used to develop appropriate prescrib-
ing patterns to preserve antimicrobial activity.
Moreover, susceptibility data may not be accurate because
surrogate methods, such as class-representative disk testing,
are used in many institutions (23). Fuchs et al. (24) found that
an accurate prediction of levofloxacin resistance could not be
derived from use of ciprofloxacin or ofloxacin disk testing.
This study showed that levofloxacin MICs were underesti-
mated. Accordingly, the drug whose clinical use is being con-
sidered must be tested directly. 
After observing three failures in patients treated with levo-
floxacin for pneumococcal infections, Davidson et al. con-
ducted a survey in 2000 (25) and found that 86% of Canadian
laboratories tested only nonfluoroquinolone antimicrobial
agents for S. pneumoniae susceptibility. Given the growing
resistance to traditional first-line agents and the increasing
number of guidelines promoting quinolones as an alternative
first-line choice in some patients (26–28), relevant testing
should be routinely performed. Highlighting the need for fluo-
roquinolone susceptibility testing, Sahm et al. (29) noted a sig-
nificant (p<0.005) increase in pneumococcal levofloxacin
resistance in1997–1998 and 1998–1999 from 0.1% to 0.6%,
although the incidence of S. pneumoniae resistance to fluoro-
quinolones remains low (<1%) in the United States (30,31). 
Resistance Selection in vitro: 
Mechanisms and Implications
Pathogenic bacteria employ a variety of strategies to per-
sist and replicate under adverse conditions such as exposure to
an antimicrobial agent. The efflux pump system is a mecha-
nism that allows immediate survival of bacteria in the presence
of an antimicrobial agent by actively expelling that agent
across the cell membrane, thereby reducing the intracellular
concentrations to sublethal levels. The pump’s action is depen-
dent on the antimicrobial’s ability to bind to the bacterial
efflux protein and be exported. Some fluoroquinolones, such
as moxifloxacin and trovafloxacin, are not as affected by bac-
terial efflux mechanisms because of their bulky side-chain
moiety at position 7, which hinders export (32). 
Another resistance mechanism involves specific point
mutations that reduce the binding of the antimicrobial agent to
specific enzymatic sites by altering the target site. In this
regard, fluoroquinolones bind to enzymes involved in DNA
replication, including DNA gyrase and DNA topoisomerase
IV. Specific mutations in the genes that code for these enzymes
can result in decreased binding and activity of the fluoroquino-
lones (33). Different fluoroquinolones demonstrate stronger or
weaker affinity to these enzyme-binding sites. First- and sec-
ond-generation fluoroquinolones bind primarily to DNA
gyrase or DNA topoisomerase IV, depending on the bacteria
and the drug, whereas the third-generation fluoroquinolones
generally bind strongly to both DNA gyrase and DNA topoi-
somerase IV. Thus, a single point mutation in DNA gyrase or
DNA topoisomerase IV generally affects first- and second-
generation fluoroquinolones to a greater extent than third-gen-
eration fluoroquinolones. Furthermore, the third-generation C-
8 methoxyfluoroquinolones, moxifloxacin and gatifloxacin,
appear to bind different molecular sites within these enzymes,
thereby decreasing the cross-resistance between these agents
and the older fluoroquinolones (34,35).
The rate at which resistance develops to an antimicrobial
agent is a measure of the resistance potential of the agent and
can be assessed in vitro. M’Zali et al. (36) compared the
mutant selecting potential of ciprofloxacin and levofloxacin in
Pseudomonas aeruginosa. In this study, clinical isolates of P.
aeruginosa were repeatedly exposed to concentrations below
the MICs for ciprofloxacin and levofloxacin. The fluoroqui-
nolone-resistant strains emerged at a significantly increased
rate with levofloxacin compared to ciprofloxacin (p<0.001).
These findings were consistent with those of Gilbert et al. (37). 
Likewise, Dalhoff et al. (38) compared the resistance selec-
tion potential of various fluoroquinolones in vitro after repeated
overnight exposures to suboptimal concentrations of S. pneu-
moniae. In this study, the C-8-methoxyquinolones (moxifloxa-
cin and gatifloxacin) showed a lower propensity to select
resistant mutants compared with levofloxacin and ofloxacin. 
Appropriate Fluoroquinolone Selection: 
Pharmacokinetic and Pharmacodynamic 
Considerations
Pharmacokinetic properties, including the concentration of
drug in the serum over time (area under the curve [AUC]) and
the peak serum concentration of the drug (Cmax), can be mea-
sured, and when considered in combination with in vitro activ-
ity, may be useful for predicting microbiologic success and
clinical outcomes. In particular, the ratio of the Cmax to MIC
or AUC to MIC (AUIC) can be predictive of drug efficacy,
although which parameter is most predictive of clinical out-
come is the subject of some disagreement. Generally, the
higher the ratio, the better the outcome (39,40). PERSPECTIVES
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While fluoroquinolones are generally concentration-
dependent bactericidal agents, differences in antibacterial
activities exist among class members. Fluoroquinolones also
differ in pharmacokinetic parameters, such as Cmax and
AUC (39). These efficacy parameters, as they relate to S.
pneumoniae and P. aeruginosa, for ciprofloxacin, levofloxa-
cin, moxifloxacin, and gatifloxacin are shown in Table 2.
Cmax/MIC and AUIC are highest for ciprofloxacin against P.
aeruginosa; against S. pneumoniae, these values are highest
with moxifloxacin. 
Although AUC/MIC and Cmax/MIC ratios are useful for
predicting antimicrobial efficacy, they may not be as useful for
predicting the potential for drug resistance to develop. In this
regard, Thomas et al. (45) suggest that AUC/MIC should
exceed 100 for gram-positive and gram-negative species to
prevent resistance selection. 
Alternatively, Zhao et al. (46) have hypothesized that the
rate at which resistance develops to a fluoroquinolone is
related to its MICs and mutant prevention concentrations.
Studies involving a range of bacterial species suggest that the
concentration to prevent mutant emergence in the clinical set-
ting can be derived in vitro and is 2 to 4 times higher than the
MIC for most fluoroquinolones (46); however, the clinical sig-
nificance of these findings has not been clearly established.
Derivation of the mutant prevention concentrations is a process
involving spreading a high bacterial load onto a series of agar
plates in which various concentrations of antimicrobial have
been incorporated. The density of 1010 CFU/mL was selected
to pinpoint frequency of mutation at levels of 10-7, 10-8, and
10-9, as well as to model the bacterial load at the site of infec-
tion. The inoculated plates are incubated overnight and the
MIC of surviving colonies determined. This method has been
applied to two species, S. pneumoniae and P. aeruginosa, for
several fluoroquinolones (Table 3) (47,48). 
Moxifloxacin exceeds the mutant prevention concentra-
tions for S. pneumoniae, and ciprofloxacin exceeds the mutant
prevention concentration for P. aeruginosa (both, 2 mg/L) by
achieving maximum serum concentrations of 4.5 mg/L and 3.0
mg/L, respectively. These serum concentrations significantly
exceed the mutant prevention concentrations; therefore, these
agents are postulated to prevent mutant selection of S. pneu-
moniae and P. aeruginosa, respectively. Levofloxacin does not
achieve mutant prevention concentrations of 8 mg/L in serum
and thus may not inhibit mutant selection (47,48). 
Clinical Consequences of Inappropriate Use
Approval of ciprofloxacin in the United States in 1987 was
accompanied by its rapid inclusion onto most hospital formu-
laries. Initial use was predominantly for P. aeruginosa and
other problematic gram-negative infections. However, after
ofloxacin was introduced in 1992, some formularies substi-
tuted this drug for ciprofloxacin on the basis of cost alone.
Similarly, levofloxacin was approved by the U.S. Food and
Drug Administration in 1997–1998 for a broad range of infec-
tions and was added to formularies in an effort to reduce costs.
The clinical consequences of these substitutions was not
apparent at the time; however, the epidemiologic data soon
emerged that reflected how varying levels of antimicrobial
activity could make an impact on pathogen susceptibility and
clinical outcomes. 
Peterson and colleagues (49) noted decreases in P. aerugi-
nosa susceptibilities to ciprofloxacin and ofloxacin of 21%
and 23%, respectively, from 1992 to 1994. This decrease
occurred after their medical center switched from ciprofloxa-
cin to ofloxacin as the primary quinolone. In 1994, ciprofloxa-
cin was reintroduced as the primary quinolone, and a 7%
recovery in ciprofloxacin activity to P. aeruginosa was
reported within 6 months. 
Similarly, Rifenburg et al. (50) assessed the effect of fluo-
roquinolone usage on P. aeruginosa susceptibilities and col-
lated data from 109 hospitals during 1993 to 1996. Greater use
of ofloxacin was associated with lower P. aeruginosa suscepti-
bilities. Bhavnani et al. (51) collected data from 145 hospitals
and found a significant correlation between use of ofloxacin,
but not ciprofloxacin, and decreasing P. aeruginosa suscepti-
bilities. Additionally, the study suggested a deleterious effect
of levofloxacin use on P. aeruginosa susceptibilities (51). 
Introduction of levofloxacin in 1998 to replace ciprofloxa-
cin in a tertiary-care university medical center resulted in a
significant decrease in P. aeruginosa susceptibilities (from
74% to 57% in a 3-year period) and E. coli susceptibility to
ciprofloxacin (from 99% to 89% in a 3-year period). Levoflox-
acin use rose from 91.2 to 272.8 defined daily dose (DDD)/
1,000 patient days (199%) in the 3-year period (52). This vol-
Table 2. Comparison of pharmacokinetic and pharmacodynamic parameters for four fluoroquinolones and selected bacterial speciesa
Streptococcus pneumoniae Pseudomonas aeruginosa
Fluoroquinolone Dose (mg) Cmaxa,b (mg/L) AUC24
b (mg x h/L) MICc Cmax:MIC AUIC MICc Cmax:MIC AUIC
Ciprofloxacin 500 3.0 28 2 1.5 14 4 0.75 7
750 3.6 32 2 1.8 16 4 0.9 8
Levofloxacin 500 5.7 48 1 5.7 48 16 0.36 3
Moxifloxacin 400 4.5 48 0.25 18 192 8 0.56 6
Gatifloxacin 400 4.2 34 0.5 8.4 68 8 0.52 4.25
aCmax, peak serum concentration of the drug; AUC, area under the curve; MIC, AUIC, ratio of the AUC to MIC.
bReferences 41–44.
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ume of usage exceeds that of 50 DDD/1,000 patients, a thresh-
old suggested by Austin et al. (53) as a predictive driver in
selecting for antimicrobial resistance during a 2-year period.
Zambrano et al. (54), at the same institution, recently reported
a significant correlation between increased levofloxacin use
and declining fluoroquinolone susceptibilities among ICU iso-
lates of K. pneumoniae (96% to 79% [p<0.008]) and P. aerugi-
nosa (82% to 67% [p<0.01]).
Similarly, another group reported (55) that after levofloxa-
cin was added to the formulary, levofloxacin use as a propor-
tion of total fluoroquinolone use increased from <2% to >22%
over a 6-month period (from 3rd quarter 1999 to 1st quarter
2000). During the period of 1st quarter 1998 to 2nd quarter
2000, the susceptibility of P. aeruginosa to ciprofloxacin
decreased by 11% (82% to 71%). The use of parenteral antip-
seudomonal agents such as gentamicin, imipenem, ceftazi-
dime, and piperacillin/tazobactam increased concurrently,
suggesting that physicians began using non-fluoroquinolone
combination therapy when treating serious gram-negative
infections. Furthermore, the antimicrobial cost reductions
anticipated from switching to a less expensive fluoroquinolone
on formulary were not realized. In 3rd quarter 2000, levofloxa-
cin was replaced with ciprofloxacin as the main gram-negative
fluoroquinolone, a substitution associated with a subsequent
6% increase in ciprofloxacin activity against P. aeruginosa
during the next year.
Because the ICU has been a focal point of antimicrobial
resistance, the Centers for Disease Control and Prevention ini-
tiated Project ICARE in 1996 (56). Specific data regarding flu-
oroquinolone use and fluoroquinolone susceptibility among P.
aeruginosa isolates were presented for the period 1996–1999
by Hill et al. (57). No correlation was found between preva-
lence of quinolone resistance and total use of ciprofloxacin/
ofloxacin. However, significant associations were found
between fluoroquinolone resistance and combined use of
ciprofloxacin, ofloxacin, and levofloxacin (p<0.019) and by
use of levofloxacin alone (p<0.006) (57). 
Likewise, recent studies suggest that using a less potent
fluoroquinolone against S. pneumoniae for treating community
and hospital respiratory tract infections may be affecting the
activity of all fluoroquinolones against this respiratory patho-
gen (58–60). Fluoroquinolone resistance in S. pneumoniae has
been reported, most notably from Hong Kong (58). A 1998
study of 181 S. pneumoniae isolates showed resistance to
ciprofloxacin in 12.1%, to levofloxacin in 5.5%, and to trova-
floxacin in 2.2%. By early 2000, levofloxacin resistance had
increased to include 13.3% of all S. pneumoniae and 27.3%
among penicillin-resistant strains (59). These strains also dem-
onstrated elevated MICs to newer class members such as gati-
floxacin (12.8%) and moxifloxacin (12.2%) (the latter
occurring exclusively in highly penicillin-resistant strains).
Additionally, fluoroquinolone resistance appears to be emerg-
ing in other countries such as Canada, where resistance rates
have increased from 0% in 1993 to 1.7% in 1997/1998 com-
bined (60). 
Clinical Consequences of Inappropriate 
Fluoroquinolone Use
Inappropriate use of antimicrobial agents has been associ-
ated with adverse consequences, including therapeutic failure,
development of resistance, and increased health-care costs.
One example of a mismatch between pharmacodynamics and
clinical infection was in the use of ciprofloxacin for commu-
nity-acquired pneumonia. The pharmacodynamics of the dose
typically prescribed in these cases (ciprofloxacin 250 mg
b.i.d.) are inappropriate for treating pneumococcal pneumonia,
especially in seriously ill patients (41). By 1994, approxi-
mately 15 cases of S. pneumoniae infections that did not
respond to ciprofloxacin had been reported, primarily in seri-
ously ill patients and associated with contraindicated medica-
tions and other important medical issues (61). These events
prompted the U.S. Food and Drug Administration to modify
the package insert to warn against empiric use of ciprofloxacin
for respiratory infections in which S. pneumoniae would be a
primary pathogen. Consequently, ciprofloxacin has been used
less frequently in these types of infections.
By contrast, >50% of levofloxacin use has been for the
treatment of respiratory infections. Since 1999, at least 20 case
reports of pulmonary infections that did not respond to levof-
loxacin therapy have been published (25,62–69). Three of the
patients died due to fulminant pneumococcal infections that
were unresponsive to levofloxacin therapy at approved dosage
(25,62,69). Very few of these cases were in immunosuppressed
patients. Reports of pneumococcal failures on the standard
dosage of levofloxacin, 500 mg every 24 h, have also been
described in two clinical trials, one in a patient with acute
exacerbation of chronic bronchitis and the other in a patient
with community-acquired pneumonia (70,71) (Table 4). In
some of the 21 case reports, the treatment failed, and the
pathogen developed levofloxacin resistance during therapy. 
Davidson et al. (25) recently published details of four
cases of pneumococcal pneumonia in which levofloxacin ther-
apy failed. Two of the patients had no history of prior fluoro-
quinolone use and were levofloxacin susceptible beginning
therapy, but their S. pneumoniae isolates were levofloxacin-
Table 3. Mutant prevention concentrations (MPC)a for various 
fluoroquinolones to Streptococcus pneumoniae and Pseudomonas 
aeruginosab
Fluoroquinolone
Daily dose
(mg)
Cmaxc
(mg/L)
P. aeruginosa 
MPC (mg/L)
S. pneumoniae 
MPC (mg/L)
Ciprofloxacin 500 b.i.d. 3.0 2 NRd
750 b.i.d. 3.6 2 NR
Levofloxacin 500 q.d. 5.7 8 8
Moxifloxacin 400 q.d. 4.5 NR 2
Gatifloxacin 400 q.d. 4.2 NR 4
aMPC values are derived from a study of approximately 100 isolates and are considered 
provisional; b.i.d., twice a day; q.d., once a day.
bSee references 47 and 48 for S. pneumoniae and P. aeruginosa, respectively.
cCmax, peak serum concentration of the drug (41–44).
dNR, not reported.PERSPECTIVES
6 Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003
resistant after therapy. These resultant mutants exhibited
increased MICs to the newer fluoroquinolones moxifloxacin
and gatifloxacin as well, thus decreasing those agents’ poten-
tial effectiveness. 
Both Weiss et al. (72) and Ho et al. (73) demonstrated clear
risk factors (Table 5) associated with the development of fluo-
roquinolone resistance, including prior exposure of the patient
to first- or second-generation fluoroquinolones (i.e., ciproflox-
acin, levofloxacin, and ofloxacin) and history of chronic
obstructive pulmonary disease. 
Conclusions
The fluoroquinolone class of antimicrobial agents is being
increasingly used empirically as resistance has developed to
the more traditional antimicrobial agents. Guidelines now rec-
ommend fluoroquinolones as first-line empiric therapy for uri-
nary tract infections in regions were trimethoprim/
sulfamethoxazole resistance is >10% to 20% (28), and fluoro-
quinolones are recommended as alternative empiric regimens
in some patients with community-acquired pneumonia
(26,27). Though increased use of these agents would be
expected to lead to increased resistance, a targeted approach to
fluoroquinolone prescribing, emphasizing their appropriate
use, may reduce development of antimicrobial resistance and
maintain class efficacy.
Evidence is mounting that suggests a link between inap-
propriate fluoroquinolone use, development of antimicrobial
resistance against the entire fluoroquinolone class, and clinical
failure. To maintain the activity of the fluoroquinolone class,
clinicians need to implement an evidence-based approach to
antimicrobial selection, particularly a strategy in which the
most pharmacodynamically potent fluoroquinolone is
matched, on an empiric basis when required, to anticipated
bacterial pathogens. 
Three major factors are associated with increasing resis-
tance to fluoroquinolones (74): 1) underdosing, i.e., use of a
marginally potent agent whose MIC is barely reached in serum
or infected tissues; 2) overuse of agents known to encourage
Table 4. Clinical failures of Streptococcus pneumoniae infection with levofloxacina
Risk factors
No. of cases Age Indication Coexisting conditions Prior FQ use Yr Ref. Country
1b 58 Meningitis HIV, splenectomy NR 1999 62 USA
3 NR RTI Yes 1999 63 USA
1 63 CAP COPD No 1999 64 USA
1 50 CAP COPD No 2000 65 USA
1 84 CAP COPD Yes-Lev 2000 65 USA
1 53 HAP none No 2001 66 USA
7 39–83(avg. 63) 4 CAP/3 AECB COPD (5) 5/7 (4-Lev, 1-Mox) 2001 67  USA
1 37 CAP none No 1999 25 Canada
1b 66 CAP COPD Yes-Cip + Lev 1999 25  Canada
1 80 AECB/CAP COPD, Yes-Cip 2001 25  Canada
1 64 CAP none No 2000 25 Canada
1 50 CAP COPD Yes-Lev 2001 68 USA
1b 79 CAP none N 1999 69 USA
21
Clinical trials
13 (7 on 500 mg) NR AECB COPD No 70  Neth.
4 NR CAP NR No 71 USA
24 (11)
Epidemiologic studies
16c - LRTI COPD Yes-Cip 1995-96 72 Canada
27d - LRTI COPD (17) Yes-Lev 1998-99 73  HK
43
Total 88 (74 on 500 mg) clinical/bacteriologic failures
aFQ, fluoroquinolone; NR, not reported; RTI, respiratory tract infection; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; Lev, levofloxacin; 
Mox, moxifloxacin; HAP, hospital-acquired pneumonia; AECB, acute exacerbation of chronic bronchitis;
LRTI, lower respiratory tract infection; Cip, ciprofloxacin; Neth, the Netherlands; HK, Hong Kong.
bDeath.
c3 deaths.
d4 deaths.Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 7
PERSPECTIVES
resistant mutants; and 3) the inability to readily detect and
respond to changes in antimicrobial susceptibilities. Tradi-
tional reporting of susceptibility data may be misleading and
may not readily identify initial changes in resistance patterns
or differences between agents of the same class.
To preserve fluoroquinolone activity, the activity of these
agents must be continually assessed, and these agents must be
used appropriately. The individual attributes of a given drug
should be matched with the likely pathogen at specific infec-
tive sites. Expecting a single fluoroquinolone to be suitable for
all infections is unreasonable, and excessive use of any single
fluoroquinolone for all indications will lead to resistance that
will adversely affect the entire class. 
Given the defined strategy of selecting the agent with the
best pharmacokinetic and pharmacodynamic profile against
the known or suspected pathogen, an appropriate therapeutic
choice for most serious infections, such as nosocomial pneu-
monia in which P. aeruginosa is a known or suspected patho-
gen, would currently include ciprofloxacin in combination
with an antipseudomonal β -lactam or an aminoglycoside anti-
biotic. This recommendation is based on the lower MIC90 and
mutant prevention concentrations for this fluoroquinolone
against P. aeruginosa and higher Cmax/MIC and AUC/MIC
ratios compared to other members of the class. Likewise, for
most other gram-negative infections of the skin and urinary
tract, including P. aeruginosa infections, ciprofloxacin mono-
therapy is appropriate. 
Ciprofloxacin, levofloxacin, and gatifloxain all achieve
high concentrations in urine; thus, they would all be appropri-
ate choices for treating urinary tract infections in the commu-
nity. Ciprofloxacin would be the most appropriate therapy in
cases where P. aeruginosa is a known or suspected pathogen.
For other gram-negative infections, levofloxacin or gatifloxa-
cin should be prescribed in appropriate doses to surpass the
mutant prevention concentrations at the infection site. 
For infections in which S. pneumoniae is anticipated to be
the most likely pathogen (e.g., community-acquired pneumo-
nia), moxifloxacin, which currently has the best antipneumo-
coccal pharmacodynamic activity and the lowest mutant
prevention concentrations against this organism, would repre-
sent a prudent therapeutic choice. By contrast, levofloxacin
MIC90s against S. pneumoniae are significantly higher than
those of moxifloxacin and gatifloxacin. The AUC/MICs and
Cmax/MICs are also lower for levofloxacin against S. pneu-
moniae, and serum concentrations of a standard dose of levof-
loxacin for community-acquired pneumonia do not reach the
mutant prevention concentrations for S. pneumoniae. For these
reasons, levofloxacin may not be the best choice for infections
caused by S. pneumoniae. Furthermore, recent reports of levo-
floxacin failures in cases of community-acquired pneumonia
caused by S. pneumoniae evoke concern.
The targeted strategy proposed in this review is being
implemented in a variety of institutions since the introduction
of the third-generation fluoroquinolones. Documenting the
effect of this approach on hospital susceptibilities over time
will be important. Additionally, susceptiblities in these hospi-
tals need to be compared to those in hospitals that use a single
fluoroquinolone more broadly. 
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Table 5. Risk factors for infection or colonization with fluoroquinolone-resistant Streptococcus pneumoniaea
Factor Case patients (n=27) Control patients (n=54) Odds ratio (95% CI) p value
Age (yr)b 72.5 (62.3–78.3) 75 (70–85) – 0.01
Nursing home residence 14 (52%) 7 (13%) 7.2 (2.4 to 21.6) <0.001
COPD 17 (63%)c  12 (22%) 5.9 (2.2 to 16.3) 0.001
Nosocomial origin 18 (66%) 14 (26%) 5.7 (2.1 to 15.6) 0.001
Interval from day of admission to
isolation of LRSP (days)b
7 (1–20) 1 (1–3) - <0.001
No. of prior admissionsb 4 (2–7) 1 (0–3) - <0.001
Recent hospitalization 16 (59%) 13 (24%) 4.6 (1.7 to 12.3) 0.003
Multiple hospitalization 15 (56%) 12 (22%) 4.4 (1.6 to 11.8) 0.004
Previous exposure to antimicrobial agentsd
Fluoroquinolones 8 (30%)/14 (52%) 0 (0%)/5 (9%) –/10.6 (3.2 to 34.7) <0.001/<0.001
β -lactam antibiotics 24 (89%)/25 (93%) 20 (37%)/32 (59%): 14.7 (3.9 to 55.4)/8.6 (1.8 to 40) <0.001/0.006
aCI, confidence interval; COPD, chronic obstructive pulmonary disease; LRSP, levofloxacin-resistant S. pneumoniae (73).
bMedian (interquartile range).
cColonization in 3 patients.
dExposure to antimicrobial therapy during the 6 weeks prior to hospitalization/12 months before hospitalization.PERSPECTIVES
8 Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003
References
  1. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of
antimicrobial resistance. Rev Infect Dis 1987;9:1065–78.
  2. Linden PK. Clinical implications of nosocomial gram-positive bactere-
mia and superimposed antimicrobial resistance. Am J Med
1998;104:24S–33.
  3. U.S. Congress, Office of Technology Assessment. Impacts of antibiotic-
resistant bacteria. OTA-H-629. Washington: U.S. Government Printing
Office; 1995.
  4. Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM,
Moellering RC Jr, et al. Outbreak of ceftazidime resistance caused by
extended-spectrum β -lactamases at a Massachusetts chronic-care facility.
Antimicrob Agents Chemother 1990;34:2193–9.
  5. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al.
Enterobacter bacteremia: clinical features and emergence of antibiotic
resistance during therapy. Ann Intern Med 1991;115:585–90.
  6. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial out-
break of Klebsiella infection resistant to late-generation cephalosporins.
Ann Intern Med 1993;119:353–8.
    7. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant
Klebsiella pneumoniae isolates recovered at the Cleveland Department of
Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118–24.
  8. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V, et al.
Scheduled change of antibiotic classes: a strategy to decrease the inci-
dence of ventilator-associated pneumonia. Am J Respir Crit Care Med
1997;156:1040–8.
  9. Hooper DC. New uses for new and old quinolones and the challenge of
resistance. Clin Infect Dis 2000;30:243–54.
10. Munshi MH, Sack DA, Haider K, Ahmed ZU, Rahaman MM, Morshed
MG. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae
type I. Lancet 1987;2:419–21.
11. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from
a transferable plasmid. Lancet 1998;351:797–9.
12. Phillips I, King A, Shannon K. Comparative in-vitro properties of the qui-
nolones. In: Andriole VT, editor. The quinolones. 3rd ed. San Diego: Aca-
demic Press; 2000. p. 99–137.
13. Blondeau JM. A review of the comparative in-vitro activities of 12 anti-
microbial agents, with a focus on five new ‘respiratory quinolones.’ J
Antimicrob Chemother 1999;43(Suppl B):S1–11.
14. Bauernfeind A. Comparison of the antibacterial activities of the quinolo-
nes Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin,
levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997;40:639–51.
15. Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T,
et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-
284756. Antimicrob Agents Chemother 2000;44:3351–6.
16. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, et al. A
critical review of the fluoroquinolones. Drugs 2002;62:13–59.
17. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. World-
wide prevalence of antimicrobial resistance in Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY
Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis
2001;32(Suppl. 2):S81–93.
18. Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. Comparative anti-
anaerobic activity of BMS 284756. Antimicrob Agents Chemother
2001;45:589–92.
19. Takahata M, Shimakura M, Hori R, Kizawa K, Todo Y, Minami S, et al. In
vitro and in vivo efficacies of T-3811ME (BMS-284756) against Myco-
plasma pneumoniae. Antimicrob Agents Chemother 2001;45:312–5.
20. Richardson DC, Bast D, McGeer A, Low DE. Evaluation of susceptibility
testing to detect fluoroquinolone resistance mechanisms in Streptococcus
pneumoniae. Antimicrob Agents Chemother 2001,45:1911–4.
21. Huang MB, Baker CN, Banerjee S, Tenover FC. Accuracy of the E test
for determining antimicrobial susceptibilities of staphylococci, entero-
cocci, Campylobacter jejuni and gram-negative bacteria resistant to anti-
microbial agents. J Clin Microbiol 1992,30:3243–8.
22. Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, et
al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneu-
moniae: contributions of type II topoisomerase mutations and efflux to
levels of resistance. Antimicrob Agents Chemother 2000;44:3049–54.
23. Weigel LM, Anderson GJ, Facklam RR, Tenover FC. Genetic analyses of
mutations contributing to fluoroquinolone resistance in clinical isolates of
Streptococcus pneumonia. Antimicrob Agents Chemother 2001;45:3517–23. 
24. Fuchs PC, Barry AL, Brown SD. Prevalence of resistance to three fluoro-
quinolones: assessment of levofloxacin disk test error rates and surrogate
predictors of levofloxacin susceptibility. Antimicrob Agents Chemother
1996;40:1633–9.
25. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JCS, Kibsey
P, et al. Resistance to levofloxacin and failure of treatment of pneumococ-
cal pneumonia. N Engl J Med 2002;346;747–50.
26. American Thoracic Society. Guidelines for the management of adults
with community-acquired pneumonia: diagnosis, assessment of severity,
antimicrobial therapy, and prevention. Am J Respir Crit Care Med
2001;163:1730–54.
27. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ.
Practice guidelines for the management of community-acquired pneumo-
nia in adults. Infectious Diseases Society of America. Clin Infect Dis
2000;31:347–82.
28. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE.
Guidelines for antimicrobial treatment of uncomplicated acute bacterial
cystitis and acute pyelonephritis in women. Infectious Diseases Society
of America (IDSA). Clin Infect Dis 1999;29:745–58.
29. Sahm DF, Karlowsky JA, Kelly LJ, Critchley IA, Jones ME, Thornsberry
C, et al. Need for annual surveillance of antimicrobial resistance in Strep-
tococcus pneumoniae in the United States: 2 year longitudinal analysis.
Antimicrob Agents Chemother 2001;45:1037–42.
30. Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for res-
piratory tract infections and emerging patterns of antimicrobial resis-
tance: data from the SENTRY antimicrobial surveillance program. Clin
Infect Dis 2000;31(Suppl 2):S16–23.
31. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA, Jones ME, Evangelista
AT, et al. Regional trends in antimicrobial resistance among clinical iso-
lates of Streptococcus pneumoniae, Haemophilus influenzae, and
Moraxella catarrhalis in the United States: results from the TRUST Sur-
veillance Program, 1999–2000. Clin Infect Dis 2002;34(Suppl 1):S4–16.
32. Peterson LR. Quinolone molecular structure-activity relationships: what
have we learned about improving antibacterial activity. Clin Infect Dis
2001, 33(Suppl 3):S180–6.
33. Pestova E, Beyer R, Cianciotto NP, Noskin GA, Peterson LR. Contribu-
tion of topoisomerase IV and DNA gyrase mutations in Streptococcus
pneumoniae for resistance to novel fluoroquinolones. Antimicrob Agents
Chemother 1999:43:2000–4.
34. Lu T, Zhao X, Drlica K. Gatifloxacin activity against quinolone-resistant
gyrase: allele-specific enhancement of bacteriostatic and bactericidal
activities by the C-8 methoxy group. Antimicrob Agents Chemother
1999;43:2969–74.
35. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of
moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob
Chemother 2000,45:583–90.
36. M’Zali FH, Hawkey PM, Thomson CJ. The comparative in vitro activity
of ciprofloxacin and levofloxacin against clinical strains of Pseudomonas
aeruginosa. Clin Microbiol Infect 2000;6(Suppl 1):91. Abstract WeP122.
37. Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, Dworkin
RJ, et al. Phenotypic resistance of Staphylococcus aureus, selected Enter-
obacteriaceae and Pseudomonas aeruginosa after single and multiple in
vitro exposures to ciprofloxacin, levofloxacin and trovafloxacin. Antimi-
crob Agents Chemother 2001;45:883–92.
38. Dalhoff A, Schubert S, Ullman U. Dissociated resistance among fluoro-
quinolones. J Antimicrob Chemother 2001;47(Suppl 1):33. abstract P67.
39. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat commu-
nity-acquired respiratory tract infections: a review of microbiologic and
pharmacokinetic-dynamic characteristics. Pharmacotherapy 2000;20:245–6.Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 9
PERSPECTIVES
40. Craig WA. Does the dose matter? Clin Infect Dis 2001;33(Suppl
3):S233–7.
41. Ciprofloxacin (Cipro) package insert. West Haven (CT): Bayer Corpora-
tion; 2001.
42. Levofloxacin (Levaquin) package insert. Rarotam (NJ): Ortho-McNeil
Pharmaceuticals; 2001.
43. Moxifloxacin (Avelox) package insert. West Haven (CT): Bayer Corpora-
tion; 2001.
44. Gatifloxacin (Tequin) package insert. Princeton (NJ): Bristol-Myers-
Squibb Pharmaceuticals, Princeton; 2001.
45. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et
al. Pharmacodynamic evaluation of factors associated the development of
bacterial resistance in acutely ill patients during therapy. Antimicrob
Agents Chemother 1998;42:521–7.
46. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants:
a general strategy derived from fluoroquinolone studies. Clin Infect Dis
2001;33(Suppl 3):S147–56.
47. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentra-
tions of fluoroquinolones for clinical isolates of Streptococcus pneumo-
niae. Antimicrob Agents Chemother 2001;45:433–8.
48. Hansen G, Blondeau JM, Drlica K, Zhao X. Evaluation of ciprofloxacin
(C) and levofloxacin (L) by mutation prevention concentration (MPC)
against 119 isolates of Pseudomonas aeruginosa (PA). In: 41st Inter-
science Conference on Antimicrobial Agents and Chemotherapy, Chi-
cago, IL, Dec 16–19, 2001. Washington: American Society for
Microbiology; 2001. Abstract E-729.
49. Peterson LR, Postelnick M, Pozdol TL, Reisberg B, Noskin GA. Manage-
ment of fluoroquinolone resistance in Pseudomonas aeruginosa—out-
come of monitored use in a referral hospital. Int J Antimicrob Agents
1998;10:207–14.
50. Rifenburg RP, Paladino JA, Bhavnani SM, Den Haese D, Schentag JJ.
Influence of fluoroquinolone purchasing patterns on antimicrobial expen-
ditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst
Pharm 1999;56:2217–23.
51. Bhavnani SM, Callen WA, Forrest A, Gilliland KK, Collins DA, Paladino
JA, et al. An evaluation of fluoroquinolone expenditures and ciprofloxa-
cin susceptibility of P. aeruginosa among U.S. hospitals. Pharmacother-
apy 2001;21(Suppl):371a. Abstract 100.
52. Peterson L. Stability of antimicrobial activity against emerging resistance
in Gram-negative pathogens recovered from hospitalized patients. In:
Program and Abstracts from the 10th International Congress on Infec-
tious Diseases, Hong Kong. March 11–14, 2002. Boston: International
Congress of Infectious Diseases; 2002. Abstract 11.029.
53. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the
volume of drug consumption in human communities and the frequency of
antibiotic resistance. Proc Natl Acad Sci U S A 1999;96:1152–6.
54. Zambrano CH, Postelnik MJ, Noskin GA. Relationship between antimi-
crobial usage and susceptibility in specific patient care areas: a 3-year
assessment. Infectious Diseases Society of America 39th Annual Meet-
ing, San Francisco, CA, Oct 25–28, 2001. Alexandria (VA): Infectious
Diseases Society of American; 2001. Abstract 496.
55. Iannini PB, Tillotson GS. Impact of quinolone substitution on Pseudomo-
nas aeruginosa resistance, antimicrobial usage and hospital costs: pre-
sented at the Antimicrobial Chemotherapy and Clinical Practice meeting,
Genova, Italy, Oct 21–24, 2001. Pharmacotherapy 2001;21(Suppl):371.
Abstract 111.
56. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE,
Archibald LK, et al. Surveillance of antimicrobial use and antimicrobial
resistance in United States hospitals: project ICARE phase 2. Clin Infect
Dis 1999;29:245–52.
57. Hill HA, Haber MJ, McGowan JE, Fridkin SK, Edwards JR, Tenover FC,
et al. A link between quinolone use and resistance in P. aeruginosa?: pre-
liminary data from Project ICARE. Infectious Diseases Society of Amer-
ica 39th Annual Meeting, San Francisco, CA, Oct 25-28, 2001.
Alexandria (VA): Infectious Diseases Society of America; 2001. Abstract
495.
58. Ho PL, Que TL, Tsang DN, Ng T-K, Chow K-H, Seto W-H. Emergence
of fluoroquinolone resistance among multiply resistant strains of Strepto-
coccus pneumoniae in Hong Kong. Antimicrob Agents Chemother
1999;43:1310–3.
59. Ho PL, Yung RWH, Tsang DN, Que TL, Ho M, Seto WH, et al. Increas-
ing resistance of Streptococcus pneumoniae to fluoroquinolones: results
of a Hong Kong multicentre study in 2000. J Antimicrob Chemother
2001;48:659–65.
60. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility
of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J
Med 1999;341:233–9.
61. Ball AP, Tillotson GS. Lower respiratory tract infection therapy – the role
of ciprofloxacin. J Int Med Res 1995;23:315–27.
62. Wortmann GW, Bennett SP. Fatal meningitis due to levofloxacin-resistant
Streptococcus pneumoniae. Clin Infect Dis 1999;29:1599–600.
63. Fishman NO, Suh B, Weigel LM, Lorber B, Gelone S, Truant AL, et al.
Three levofloxacin treatment failures of pneumococcal respiratory tract
infections. 39th Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, CA, Sept 26–29, 1999. Washington:
American Society for Microbiology; 1999. Abstract 825.
64. Kuehnert MJ, Nolte FS, Perlino CA. Fluoroquinolone resistance in Strep-
tococcus pneumoniae. Ann Intern Med 1999;131:312–3.
65. Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, et
al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with
levofloxacin therapy. J Infect Dis 2001;184:794–8.
66. Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME. Levofloxa-
cin failure in a patient with pneumococcal pneumonia. Ann Pharmacother
2001;35:687–90.
67. Piper J, Couch K, Tuttle D, Steele-Moore L. Epidemiology and clinical
outcomes of patients with levofloxacin resistant pneumococcus. 41st
Interscience Conference on Antimicrobial Agents and Chemotherapy,
Chicago, IL, Dec 16–19, 2001. Washington: American Society for Micro-
biology; 2001. Abstract L-902.
68. Kays MB, Smith DW, Wack MF, Denys GA. Levofloxacin treatment fail-
ure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae
pneumonia. Pharmacotherapy 2002;22:395–9.
69. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and
failure of treatment of pneumoccal pneumoia. N Engl J Med;347:65–6.
70. Davies BI, Maesen FPV. Clinical effectiveness of levofloxacin in patients
with acute purulent exacerbations of chronic bronchitis: the relationship
with in-vitro activity. J Antimicrob Chemother 1999;43(Suppl C):83–90.
71. Sullivan JG, McElroy AD, Honsinger RW, McAdoo M, Harrison BJ,
Plouffe JF, et al. Treating community-acquired pneumonia with once
daily gatifloxacin vs once-daily levofloxacin. Journal of Respiratory Dis-
eases 1999;20(Suppl):S49–59.
72. Weiss K, Restieri C, Gauthier R, Laverdiere M, McGeer A, Davidson R,
et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus
pneumoniae. Clin Infect Dis 2001;33:517–22.
73. Ho PL, Tse WS, Tsang KWT, Kwok TK, Ng TK, Cheng VCC, et al. Risk
factors for acquisition of levofloxacin-resistant Streptococcus pneumo-
niae: a case-control study. Clin Infect Dis 2001;32:701–7.
74. Thomson KS. Minimizing quinolone resistance: are the new agents more or
less likely to cause resistance? J Antimicrob Chemother 2000;45:719–23.
Address for correspondence: W. Michael Scheld, Professor of Medicine and
Neurosurgery,  University of Virginia, School of Medicine, Box 801342,
Charlottesville, VA 22908, USA; fax: 434-924-2885; e-mail: wms@
Virginia.EDU
All material published in Emerging Infectious Diseases is in the public
domain and may be used and reprinted without special permission; proper
citation, however, is required.